The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The chief executive of Muscular Dystrophy UK and interim chief executive of Myaware UK have shared thoughts on the rejection ...

AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised ...